Vinayak Venkataraman

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Acute Lymphoblastic Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Pediatric blood & cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Gregory M Cote, Candace L Haddox, Edwin Choy, Priscilla A Merriam, Emanuele Mazzola, Vinayak Venkataraman, Thierry Alcindor, Andrew J Wagner, George D Demetri, Suzanne George
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Gregory M Cote, Candace L Haddox, Edwin Choy, Priscilla A Merriam, Emanuele Mazzola, Vinayak Venkataraman, Thierry Alcindor, Andrew J Wagner, George D Demetri, Suzanne George
Safety And Efficacy Of Combination Lurbinectedin Plus Doxorubicin From A Phase 1b Trial In Patients With Advanced/Metastatic Soft Tissue Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Vinayak Venkataraman, Bailey A Martin-Giacalone, Bettina F Drake, Liz Salmi, Elizabeth B Claus, Anne L R Schuster, John F P Bridges, Heinz-Josef Lenz, Cheryl L Willman, Diane Diehl, Katherine A Janeway, Jennifer W Mack, Suzanne George
Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Vinayak Venkataraman, Suzanne George, Gregory M Cote
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor. The oncologist (2023)
Vinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, Alison M Friedmann
Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy. Pediatric blood & cancer 68 (10) (2021)
Vinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, Alison M Friedmann
Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. Pediatric blood & cancer 67 (5) (2020)